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p < 0.001. The average of referrals was of 70.5 per 100 attended-
patients/year (p < 0.001). 2.5% referrals of the total were made
to the neurological, being patient of greater age, with predomi-
nance of women and displaying the head pain/migraine as main
consultation reason. Visits and episodes explain 43.2%-73.9%
respectively (p < 0.001), the explanatory power of the classiﬁca-
tion’s variability was of 46.3% (p = 0.001) and the referral
20.1%. EI per center were: 0.97 (CI: 0.77–1.18), 0.79 (CI: 0.57–
1.01), 0.88 (CI: 0.62–1.14), 1.29 (CI: 0.94–1.65) and 0.91 (CI:
0.58–1.25), p = 0.023 (family practice) and 0.90 (CI: 0.47–1.33),
0.78 (CI: 0.35–1.21), 0.93 (CI: 0.43–1.44), 1.21 (CI: 0.60–1.82)
and 0.97 (CI: 0.39–1.56), p = 0.031 (pediatrics); respectively.
CONCLUSIONS: Adjusted morbidity by ACG explains an
important part of the referrals variability. A low percentage was
derived to neurology.The study results must be interpreted cau-
tiously even after adjustment by age, gender and morbidity.
Should the results be conﬁrmed it would allow an improvement
in the measurement of referrals for clinical management in the
PCT.
PND30
NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS
TREATMENT IN BRAZILIAN PUBLIC HEALTH:AN ANALYSIS
OFTREATMENT PATTERNS AND BUDGET IMPACT
Bueno RLP, Pereira MF
FEI, São Paulo, Brazil
OBJECTIVES: To determine the budget impact of treatment
patterns for Multiple Sclerosis (MS) based on national guideline.
METHODS: A one-year (October 2006 to September 2007)
retrospective database search was conducted to identify medica-
tion used, costs, patient adherence and provision. The source of
data was the Ministry of Health public available database, called
DATASUS. The study were conduct in four steps: 1) Determine
the medicines codes in the public list; 2) Establish the relation-
ships among drugs and patients usage, based on national guide-
lines; 3) Analyze adherence pattern in the most relevant center in
Brazil, based on medication consumption; and 4) Determine the
budget impact for MS treatment. RESULTS: Medication for MS
was responsible by 13% of high cost medication supplied by
Public Sector in Brazil. During the period of analysis the costs
and number of patients grew more than 100%, in average
60,000 medications per month were supplied and a total 8.294
patients were treated. Patients treated were distributed among
therapeutics alternative as follow: 60.28% to interferon-1a (two
brands), 19.99% to interferon-1b and 19.74 to glatiramer
acetate. Five states out of 27 were responsible by 80% of patients
treated. It was possible to detect the beginning of drug associa-
tion. We found that 26% of patients adhere to disease treatment.
Treatment costs was higher than USD 9 millions per month, the
distribution of costs is similar to the patients distribution due to
fewer combination therapy. CONCLUSIONS: National guide-
lines permits universal access, but the analysis of treatment pat-
terns points to a high concentration of care and this could be an
indicator of health care provision inequalities. Due to the high
costs of treatments and the fast patient growth rates new cost-
efﬁcient alternatives need to be considered as a way to reduce
health system inequalities.
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DESCRIPTIVE STUDY OFTHE PHARMACOLOGICAL
TREATMENTS USED IN PATIENTS WITH DEPRESSION IN
PARKINSON’S DISEASE (PD)
Sunderland TJ, Lee S, Das Gupta R
Boehringer Ingelheim, Bracknell, UK
Depression affects around 40–50% of people with PD [Goetz
2002]. It has been argued that depression in PD can be consid-
ered to be one of the manifestations of the degenerative nature of
the disease on the CNS [Shrag et al 2000]. Any differences in the
aetiology and co-morbidities in depression in PD when compared
to depression in those without PD may result in differences in
antidepressant treatment patterns. Furthermore, certain PD
drugs are metabolised in a way that may lead to their interaction
with certain antidepressants. Awareness of this may impact upon
prescribing decisions both for antidepressant and PD drugs in
those with depression in PD. OBJECTIVES: The objective of this
study is to describe the use of antidepressants in the treatment of
depression in PD patients. METHODS: The study was carried
out using the General Practice Research Database (GPRD). The
GPRD is a database with 9 million patients’ data (3.7 million
being currently active). The search identiﬁed PD patients on
various rates of different antidepressants. The PD patients were
diagnosed with PD from 2002 onwards. RESULTS: The study
identiﬁed 18,481 patients with a diagnosis of PD; 44% of these
also had a diagnosed depression (8,058 of 18,481). Of these PD
patients with depression, 21% had prescriptions for Amitrip-
tyline (1658 of 8058), 19% for Fluoxetine (1549 of 8058),
14% for Citalopram (1125 of 8058), 7% for Venlafaxine
(566 of 8,058) and 5% for Mirtazapine (369 of 8058).
CONCLUSIONS: This study conﬁrms the results of previous
studies that there is a high prevalence of depression in PD patients.
Within a UK context, the study also identiﬁes that a large propor-
tion of these patients receive antidepressant treatments.
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OBJECTIVES: To evaluate the risk of psychiatric disorders and
associated health care expenditures among moderate to severe
psoriasis (PsO) patients using data from a US health care claims
database. METHODS: PsO patients and controls without PsO
were identiﬁed from the PharMetrics health care claims database
using the ICD-9 code of 696.x. Patients with moderate to severe
PsO (N = 7971) had been diagnosed with PsO in both years 2003
and 2004, and had been treated with systemic therapies including
cyclosporine, methotrexate, acitretin, biologics, or phototherapy.
Controls (N = 31884) were matched with PsO cases in a 4:1 ratio
by gender, age, region, and previous time-in-plan. Psychiatric
disorders and anti-psychiatric therapies in year 2004 were com-
pared between groups. RESULTS: PsO cases were equally distrib-
uted between males (50.6%) and females with mean age of 47.2
years. Almost half of the patients received anti-inﬂammatory
drugs, 33.3% received biologic therapies, and 36.7% had photo-
therapy. Compared with controls, patients with moderate to
severe PsO had a statistically signiﬁcantly higher prevalence
(p < 0.01) of anxiety (6.94% vs. 4.37%, OR = 1.63), depression
(9.17% vs. 5.32%, OR = 1.80), bipolar disorder (1.10% vs.
0.51%,OR = 2.16), and delirium (0.25%vs. 0.14%,OR = 1.74).
There was no difference between PsO patients and controls in the
prevalence of dementia or schizophrenia (p > 0.05). Compared
with controls, a greater proportion of PsO patients had been
treated with antidepressants (6.12% vs. 0.90%, OR = 7.18),
anxiolytics (5.03% vs. 0.75%, OR = 7.04), anti-psychotics
(5.90% vs. 0.89%, OR = 6.97) or anti-manics (4.89% vs.
0.74%, OR = 6.93). PsO patients had higher total health care
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expenditures ($11,538.8) than controls ($42,18.7, p < 0.0001).
Among the PsO patients, those with any psychiatric disorders had
a total health care expenditure of $18,046.70, as compared with
$10,503.50 for those without psychiatric disorders (p < 0.0001).
CONCLUSIONS: PsO patients have a signiﬁcantly higher preva-
lence of psychiatric disorders as compared with patients without
PsO. PsO patients with psychiatric disorders have signiﬁcantly
higher health care expenditure than those without such disorders.
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OBJECTIVES: To determine the proportion of cataract patients
requiring glasses at least 18 months after a bilateral implantation
of the ReSTOR(r) multifocal IOL, assess post-operative patient
satisfaction, and identify factors contributing to post-operative
eyeglass independence. METHODS: This cross-sectional study
was performed in France and Spain. Patients were selected at
random from medical charts of 10 centers. Medical data and
surgical procedure characteristics were collected retrospectively
from patient charts. A new speciﬁc scale, the Freedom from
Glasses Value Scale (FGVS) was administered to patients by
phone interview. FGVS scores range from 1 to 5, with 5 being the
most favourable score. A Bayesian network was constructed to
predict post-operative spectacle wear using FGVS items and
scores. RESULTS: A total of 304 patients with a mean age of
65.6 years were included. On average, the last eye surgery was
carried out 2.0 years before survey administration. Pre-
operatively, 62.5% of patients had a Snellen decimal distance
visual acuity superior to 0.8. Post-operative acuity was better
than 0.8 for 93.3% and 88.6% of the patients’ uncorrected near
and distance vision, respectively. Whereas 93.4% of patients
wore glasses before surgery, 87.2% were spectacle free after
surgery. Patients were very satisﬁed: 88% indicated that since
surgery their vision was better and 93% thought the surgery
produced a positive change. FGVS mean scores were: 3.81 and
3.80 respectively for practical and psychological advantages;
4.52 for evaluation of the result; 4.41 for feelings; and 4.47 for
global judgment. The Bayesian network demonstrated two con-
tributors to postoperative spectacle independence. Patients who
perceive considerable bother associated with wearing glasses,
and those sensitive to the opinions of others about their appear-
ance without glasses, are 3 times less likely to wear glasses
post-operatively. CONCLUSIONS:These study results conﬁrm
clinical trial ﬁndings. In actual medical practice over multiple
years, ReSTOR® IOL implantation provides both good distance
and near vision, a high level of spectacle independence, and high
patient satisfaction. Beyond good results from the lens, a desire
for spectacle freedom contributes to post-operative independence
from eyeglasses
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OBJECTIVES: The aim of this study was to compare vision 6
months after cataract surgery in patients implanted with one of
three IOLs: a monofocal or a multifocal (ReSTOR® or ARRAY-
SA40®). The latter two often free patients from spectacles for
near and distance vision. METHODS: A randomized clinical
trial comparing ARRAY-SA40® with a monofocal was pooled
with a prospective cohort of patients implanted with ReSTOR®.
Patient satisfaction, spectacle freedom rate, and corrected and
uncorrected, near and distance visual acuities (VA) were mea-
sured six months after surgery. Treatment group comparability
was checked at baseline. Imbalances on confounding factors
were adjusted using both linear models and propensity scores.
RESULTS: Sixtry-nine patients had a monofocal, 68 received the
ARRAY-SA40® and 83 were implanted with ReSTOR®.
ReSTOR® patients were younger (P < 0.0001) and had a lower
neuroticism score (P < 0.001). The sex-ratio was six females-
: four males. VA and spectacle dependency at baseline were com-
parable. At 6 months no difference was observed on distance VA,
corrected or uncorrected. Uncorrected near VA of ReSTOR®
patients was better (P < 0.0001) than with either a monofocal
IOL or ARRAY-SA40®. The probability of being free of spec-
tacles with ReSTOR was higher (P < 0.0001) than with a mono-
focal (RR = 10.2) or an ARRAY-SA40® (RR = 10.7). ReSTOR®
patients wearing spectacles never had multifocal glasses (the
most expensive), while 32% of ARRAY-SA40® and 52% of the
monofocal patients did. Good or excellent near vision satisfac-
tion with ReSTOR® was more often reported by patients than
with the ARRAY-SA40® or a monofocal (83.6%, 32.4%, 26.1%,
respectively; P < 0.0001). The corresponding satisfaction differ-
ence did not reach statistical signiﬁcance with distance vision
(82.1%, 75.0%, 67.7%, respectively; P < 0.17). Linear and pro-
pensity score adjustments did not modify the results. CONCLU-
SIONS: The uncorrected distance VA of the three IOLs was
similar. Near uncorrected VA in ReSTOR® patients was better
than in patients implanted with a monofocal or ARRAY-SA40®,
resulting in a higher spectacle independence rate and better near
vision patient satisfaction.
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RATE COMPARISON ONEYEAR AFTER SURGERY
Gauthier L1, Lafuma A2, Laurendeau C2, Berdeaux G3
1Polyclinique Côte Basque Sud, Saint jean de Luz, France,
2Cemka-Eval, Bourg-la-Reine, France, 3Alcon France, Rueil-Malmaison,
France
OBJECTIVES: The aim of this study was to compare the one
year Nd:Yag laser incidence rate of two multifocal intra-ocular
lenses, ReSTOR® and Acrilisa®, implanted by a single surgeon
following his usual practices METHODS: This retrospective
study was based on all patients implanted with a ReSTOR® or
Acrilisa® multi-focal lens since the third trimester of 2004 at one
site. All patients with either cataract or clear lens were operated
by the same surgeon. Characteristics of the subjects, as well as
pre and post-op medical data were obtained from patient charts.
One year post surgical data were obtained from the surgeon’s
medical ﬁles and from other ophthalmologists, if any, involved in
post-surgical care. Time to Nd:Yag laser analysis was carried out
using Kaplan-Meier survival curves. Imbalance on confounding
variables was adjusted with a Cox model. RESULTS: Eighty
patients were bilaterally implanted with ReSTOR® and 76 with
Acrilisa®. Patients with ReSTOR® were more often male (52.5%
versus 30.7%; P < 0.001) and younger (63.1 versus 65.8;
P < 0.001). After one year of follow-up, 3.7% of the ReSTOR®
eyes had Nd:Yag laser versus 11.6% of the Acrilisa® eyes. Gender
was not found to be associated with Nd:Yag laser while older
patients were less prone to have capsulotomy (RR = 0.91,
IC95% [0.83–1.00], P = 0.05). Eyes with Acrilisa® had 3.54
A610 Abstracts
